NXL · CIK 0001527352 · operating
# Nexalin Technology, Inc.
Based in Houston, Texas, Nexalin Technology develops neurostimulation medical devices designed to treat mental health and neurological conditions. The company's product line utilizes bioelectronic technology to deliver treatment without pharmaceutical intervention or psychotherapy. Its Generation 1 device targets anxiety, insomnia, and depression through an easy-to-administer format. Generation 2 and Generation 3 headset devices address a broader therapeutic scope, including depression, substance use disorders, post-traumatic stress disorder, traumatic brain injury, opioid addiction, alcoholism, chronic pain, Alzheimer's disease, and dementia.
The company operates primarily in the United States and China. Nexalin maintains a minimal operational footprint with six full-time employees. The company is incorporated in Delaware and trades on the Nasdaq exchange. Specific information regarding revenue segments, sales channels, or regulatory clearance status is not currently available.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.83 | $-0.83 | -31.7% | |
| 2023 | $-0.63 | $-0.63 | — | |
| 2022 | — | — | — |